Lumos Diagnostics Holdings Limited

Reported revenue for Q3 FY26 was $4.8 million, versus $3.47 million in the prior corresponding period, up 37% year on year. Product revenue was $2.4 million versus $0.7 million a year earlier, while services revenue was $2.4 million versus $2.8 million previously, with the company noting Q3 IP revenue was $0.8 million lower than the prior corresponding period. Year-to-date revenue was $10.9 million, up 11% year on year, and management said FebriDx sales were about $3.9 million year to date. Net cash outflow for the quarter was $3.1 million, compared with $1.6 million in the prior corresponding period, and cash at March 31 was $1.1 million. Guidance-wise, management did not give formal revenue guidance; instead, it said the next phase is commercialization of the CLIA-waived FebriDx launch, scale-up manufacturing for PHASE, and continued rollout through urgent care and primary care channels.

Douglas Ward framed the quarter as a transition from product approval to commercialization, calling the CLIA waiver transformational and emphasizing the scale of the U.S. opportunity. He said the company is now positioned to expand FebriDx into about 270,000 sites and to use PHASE, distributors, and targeted clinic pilots to drive adoption. His tone was upbeat and confident, but he repeatedly stressed that execution now matters more than approval.

Barrie Lambert said Q3 revenue was $4.8 million, with product revenue of $2.4 million and services revenue of $2.4 million, and he highlighted the year-to-date revenue of $10.9 million. He also noted net cash outflow of $3.1 million in the quarter and a March cash balance of $1.1 million, while pointing to post-quarter cash receipts including $20 million from the placement, a $5 million PHASE prepayment, and an expected $0.5 million BARDA milestone payment. On commercial economics, management said the PLA code was set at $41.38, FebriDx starts at about 60% gross margin, and margins could rise to about 80% over the PHASE agreement period.

Analysts asked about Australian Medicare reimbursement, and management said it is still pursuing that route after an initial attempt failed, now planning a larger comparative study with the University of Wollongong. Questions also focused on whether U.S. antibiotic-stewardship policy could help, and management said the policy is supportive but will take time to translate into usage. On commercialization, management said PHASE is responsible for distributor execution while Lumos is handling reimbursement and awareness, and it said the company is not yet ready to provide revenue guidance or regular marketing-spend impact updates.